Lagevrio

Basic Lagevrio information

• INN (international nonproprietary name): Molnupiravir
• Brand names available in the United Kingdom: Lagevrio
• ATC code: J05AB18
• Forms and dosages: 200 mg capsules; regimen 4 capsules (800 mg) twice daily for 5 days (40 capsules per course)
• Manufacturers in the United Kingdom: Merck Sharp & Dohme (MSD)
• Registration status in the United Kingdom: Conditional marketing authorisation (MHRA)
• OTC / Rx classification: Prescription-only medicine (POM)

Everyday use and best practices

Lagevrio (molnupiravir) is taken twice daily, about 12 hours apart, for 5 days. Taking it consistently is important in managing mild-to-moderate COVID-19. Many people link their morning and evening doses with routine activities such as meals, which makes it easier to remember. Treatment should begin within five days of symptom onset.

Taking with or without meals

Lagevrio can be taken with or without food. Taking it with food may reduce nausea or an upset stomach. Swallow the capsules whole with water.

Legal status in the UK

Lagevrio is a prescription-only medicine (POM) in the UK.

What’s inside and how it works

The active component of Lagevrio is molnupiravir, with each capsule containing 200 mg of this antiviral agent. The capsules also contain excipients. The patient information leaflet lists all the ingredients.

Mechanism basics explained simply

Molnupiravir interferes with the replication process of the SARS-CoV-2 virus by introducing errors in its RNA. This disruption inhibits the virus's ability to multiply effectively, allowing the body's immune system to combat the infection more efficiently.

Main indications

This antiviral medication is used to treat mild-to-moderate COVID-19 in adults at high risk of severe disease progression.

Approved uses (MHRA listing)

Lagevrio has a conditional marketing authorisation from the MHRA for treating mild-to-moderate COVID-19 in adults with at least one risk factor for developing severe illness. Treatment should start within five days of the onset of symptoms.

Off-label uses in UK clinics

Any use outside the licensed indication should only follow a discussion between the patient and a healthcare professional about the benefits and risks.

Interaction warnings

Food interactions (alcohol, tea/coffee)

No specific food interactions with Lagevrio have been documented. Alcohol consumption is not recommended during treatment. Tea or coffee is generally acceptable.

Drug conflicts

Few drug interactions have been identified, but tell your healthcare provider or pharmacist about all medicines you take. Suspected side effects can be reported through the Yellow Card scheme.